LEXARIA BIOSCIENCE CORP. Exploration Expense
LEXARIA BIOSCIENCE CORP. (LEXX) reported Exploration Expense of $33.54 thousand for the 6-month period ending 2025-02-28, per its 10-Q filed 2025-04-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ExplorationExpense · last filed 2025-04-14
- LEXARIA BIOSCIENCE CORP. exploration expense for the quarter ending 2025-02-28 was $9.08K, a 6.74% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. exploration expense for the quarter ending 2024-11-30 was $24.46K, a 195.65% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. exploration expense for the quarter ending 2024-02-29 was $9.73K.
- LEXARIA BIOSCIENCE CORP. exploration expense for the quarter ending 2023-11-30 was $8.27K, a 84.94% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. exploration expense for fiscal 2024 was $33.70K, a 38.65% decline from fiscal 2023.
- LEXARIA BIOSCIENCE CORP. exploration expense for fiscal 2023 was $54.94K, a 622.01% increase from fiscal 2022.
- LEXARIA BIOSCIENCE CORP. exploration expense for fiscal 2022 was $7.61K.
| Period end | Exploration Expense 3 month | Exploration Expense 6 month | Exploration Expense 12 month |
|---|---|---|---|
| 2025-02-28 | $9.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-04-14 | $33.54K 10-Q · filed 2025-04-14 | |
| 2024-11-30 | $24.46K 10-Q · filed 2025-01-10 | ||
| 2024-08-31 | $33.70K 10-K · filed 2024-11-26 | ||
| 2024-02-29 | $9.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-04-14 | $18.01K 10-Q · filed 2025-04-14 | |
| 2023-11-30 | $8.27K 10-Q · filed 2025-01-10 | ||
| 2023-08-31 | $54.94K 10-K · filed 2023-11-20 | ||
| 2022-11-30 | $54.94K 10-Q · filed 2024-01-12 | ||
| 2022-08-31 | $7.61K 10-K · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |